Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Visual Field Defect after Taking Atorvastatin/Ezetimibe, a Case Study

Atorvastatin/ezetimibe 복합제 복용 후 발생한 시야결손 부작용 사례보고

  • Kim, Jiyoon (College of Pharmacy, Gachon University) ;
  • Lee, Kyunggyu (College of Pharmacy, Gachon University) ;
  • Kim, Junyoung (College of Pharmacy, Gachon University) ;
  • Lee, Jung-Min (Regional Pharmacovigilance Center, Korean Pharmaceutical Association) ;
  • Kim, Na-Young (Regional Pharmacovigilance Center, Korean Pharmaceutical Association) ;
  • Lee, Mo-Se (Regional Pharmacovigilance Center, Korean Pharmaceutical Association) ;
  • Ji, Eunhee (College of Pharmacy, Gachon University)
  • 김지윤 (가천대학교 약학대학) ;
  • 이경규 (가천대학교 약학대학) ;
  • 김준영 (가천대학교 약학대학) ;
  • 이정민 (대한약사회 지역의약품안전센터) ;
  • 김나영 (대한약사회 지역의약품안전센터) ;
  • 이모세 (대한약사회 지역의약품안전센터) ;
  • 지은희 (가천대학교 약학대학)
  • Received : 2019.05.20
  • Accepted : 2019.06.08
  • Published : 2019.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Atorvastatin is one of the most widely prescribed medications for dyslipidemia treatment. In Korea, post combined therapy with ezetimibe, a 73-year-old woman was reported by a community pharmacy to have experienced visual field defect, which recovered after drug discontinuation. She had never experienced this symptom before, and several studies have reported an association between use of statins and visual disorders such as blurred vision, diplopia, and cataract. Blockage of cholesterol accumulation, oxidative stress, or myopathy is expected to be a cause of this symptom. Naranjo scale, Korean causality assessment algorithm (Ver.2), and World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria were the three tools used to determine causality between the visual disorder and atorvastatin. The results represent 'probable', 'certain', and 'probable/likely' causality, respectively. Our results, in combination with a review of literature, indicate that ocular adverse effects are highly likely related to atorvastatin.

Keywords

References

  1. ClinCalc.com DrugStats Database. Atorvastatin, Drug Usage Statistics, United States, 2006-2016. Available from http://clincalc.com/DrugStats/Drugs/Atorvastatin. Accessed March 10, 2019.
  2. Korean Index of Medical Specialties (KIMS). Atorvastatin. Available from http://www.kimsonline.co.kr/drugcenter/generic/geninfo/GATR0. Accessed March 10, 2019.
  3. Lee SH, Park S, Kang SM, et al. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia. J Cardiovasc Pharmacol Ther 2012;17(1):65-71. https://doi.org/10.1177/1074248411399762
  4. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107(19):2409-15. https://doi.org/10.1161/01.CIR.0000068312.21969.C8
  5. Mizranita V and Pratisto EH. Statin-associated ocular disorders: the FDA and ADRAC data. Int J Clin Pharm 2015;37(5):844-50. https://doi.org/10.1007/s11096-015-0128-x
  6. Bahrami B, Rajak S, Selva D. Orbital myositis secondary to statin therapy. Med J Aust 2015;203(9):365. https://doi.org/10.5694/mja15.00503
  7. Fraunfelder FW and Richards AB. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Ophthalmology 2008;115(12):2282-5. https://doi.org/10.1016/j.ophtha.2008.08.006
  8. Machan CM, Hrynchak PK, Irving EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci 2012;89(8):1165-71. https://doi.org/10.1097/OPX.0b013e3182644cd1
  9. Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol 1996;40(4):320-37. https://doi.org/10.1016/S0039-6257(96)82007-8
  10. Zelenka PS. Lens lipids. Curr Eye Res 1984;3(11):1337-59. https://doi.org/10.3109/02713688409007421
  11. Spurgeon D. Antibiotic use with cholesterol lowering drugs may increase risk of cataracts. BMJ 2002;325(7374):1194. https://doi.org/10.1136/bmj.325.7374.1194
  12. Kanski JJ and Bowling B. Clinical Ophthalmology: A Sytematic Approach, 7th ed. Philadelphia, PA: Elsevier 2011:269-310.
  13. Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins-mechanisms and consequences. Curr Drug Saf 2009;4(3):209-28. https://doi.org/10.2174/157488609789006949
  14. Satoh K and Ichihara K. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts. Eur J Pharmacol 1995;292(3-4):271-5. https://doi.org/10.1016/0926-6917(95)90032-2
  15. Satoh K, Yamato A, Nakai T, et al. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol 1995;116(2):1894-8. https://doi.org/10.1111/j.1476-5381.1995.tb16679.x
  16. Willis RA, Folkers K, Tucker JL, et al. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA 1990;87(22):8928-30. https://doi.org/10.1073/pnas.87.22.8928
  17. Littarru GP and Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 2007;7(suppl):S168-74. https://doi.org/10.1016/j.mito.2007.03.002
  18. Kawashiri MA, Nohara A, Tada H, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther 2008;83(5):731-9. https://doi.org/10.1038/sj.clpt.6100396
  19. Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005;31(5):572-80. https://doi.org/10.1002/mus.20291
  20. Dirks AJ and Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006;291(6):C1208-12. https://doi.org/10.1152/ajpcell.00226.2006
  21. Urso ML, Clarkson PM, Hittel D, et al. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005;25(12):2560-6. https://doi.org/10.1161/01.ATV.0000190608.28704.71
  22. Liantonio A, Giannuzzi V, Cippone V, et al. Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/ mitochondria $Ca^{2+}$-release system. J Pharmacol Exp Ther 2007;321(2):626-34. https://doi.org/10.1124/jpet.106.118331